Dr. Michael A. Levine, MD
Pediatric Endocrinology (Pediatric Endocrinology Physician)
3401 Civic Center Blvd, Children's Hospital Of Philadelphia - Endocrinology
Philadelphia, PA 19104
At a glance
- Medical school
- Hahnemann University College of Medicine (1976)
- Years since graduation
- 50
- In the NPI registry since
- 2007
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1976Medical school: Hahnemann University College of Medicine
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pediatric Endocrinology Physician primary
PA license MD434059 -
Pediatrics Physician
PA license MD434059
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Childrens Health Care Associates Inc (220 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Crysvita (burosumab-twza) | 26 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 6 companies reported 10 payments worth $15,397 in total to this clinician.
| Pharmacosmos Therapeutics Inc. | $5,642 |
|---|---|
| Alexion Pharmaceuticals, Inc. | $4,906 |
| Takeda Pharmaceuticals U.S.A., Inc. | $3,115 |
| Novo Nordisk Health Care AG | $1,000 |
| Mirum Pharmaceuticals, Inc. | $700 |
| Corcept Therapeutics | $33.50 |
| Consulting Fee | $9,721 |
|---|---|
| Honoraria | $5,454 |
| Food and Beverage | $188 |
| Education | $33.50 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Pharmacosmos Therapeutics Inc. Jul 30, 2025 | Honoraria MONOFERRIC · HEMATOLOGY | $5,454 |
| Alexion Pharmaceuticals, Inc. Apr 15, 2025 | Consulting Fee | $4,900 |
| Takeda Pharmaceuticals U.S.A., Inc. Jan 17, 2025 | Consulting Fee | $1,558 |
| Takeda Pharmaceuticals U.S.A., Inc. Jan 28, 2025 | Consulting Fee | $1,558 |
| Novo Nordisk Health Care AG Feb 7, 2025 | Consulting Fee | $1,000 |
| Mirum Pharmaceuticals, Inc. Apr 1, 2025 | Consulting Fee | $700 |
| Corcept Therapeutics Oct 10, 2025 | Education Korlym · Endocrinology · in-kind | $16.75 |
| Corcept Therapeutics Oct 10, 2025 | Education Korlym · Endocrinology · in-kind | $16.75 |
| Alexion Pharmaceuticals, Inc. Sep 15, 2025 | Consulting Fee | $6.30 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 3 companies. The companies reported $87,822 in research payments for these studies, mostly to the institutions running them.
- X-linked Hypophosphatemia Disease Monitoring Program
Ultragenyx Pharmaceutical Inc. · Active, not recruiting · NCT03651505 - Eneboparatide - Calypso study which is a pivotal phase 3 study investigational therapeutic peptide with a novel mechanism of action for hypoparathyroidism
Alexion Pharmaceuticals, Inc. - A Registry for Participants With Chronic Hypoparathyroidism
Takeda Pharmaceuticals U.S.A., Inc. · Completed · NCT01922440
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.